CIPLA
Back to Income Statement
|
CIPLA Last 5 Year Consolidated Net Profit History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Consolidated Net Profit | ₹4,122 Cr | ₹2,802 Cr | ₹2,517 Cr | ₹2,405 Cr | ₹1,547 Cr |
What is the latest Consolidated Net Profit of CIPLA ?
| Year | Consolidated Net Profit |
|---|---|
| Mar2025 | ₹4,122 Cr |
| Mar2024 | ₹2,802 Cr |
| Mar2023 | ₹2,517 Cr |
| Mar2022 | ₹2,405 Cr |
| Mar2021 | ₹1,547 Cr |
How is Consolidated Net Profit of CIPLA Trending?
| Years | Consolidated Net Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹4,122 Cr | 47.10 | |
| Mar2024 | ₹2,802 Cr | 11.33 | |
| Mar2023 | ₹2,517 Cr | 4.65 | |
| Mar2022 | ₹2,405 Cr | 55.50 | |
| Mar2021 | ₹1,547 Cr | - | |
Compare Consolidated Net Profit of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹97,848.8 Cr | 0.8% | -9.1% | -13.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹407,083.0 Cr | -3.9% | -8.9% | -3.2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹163,971.0 Cr | 3.8% | -4.7% | 11.5% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹140,660.0 Cr | 3.2% | -5.6% | 26.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹101,686.0 Cr | 3.3% | -6% | 11% | Stock Analytics | |
| MANKIND PHARMA | ₹87,624.9 Cr | 1.9% | -7.1% | -15.2% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | 0.8% |
-9.1% |
-13.1% |
| SENSEX | 3.7% |
-0.9% |
0.7% |
You may also like the below Video Courses